Kala Pharmaceuticals - KALA Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KALA, but not buy additional shares or sell existing shares.
View KALA analyst ratings or view top-rated stocks.

3 brokerages have issued 12-month target prices for Kala Pharmaceuticals' shares. Their KALA share price forecasts range from $37.50 to $100.00. On average, they expect the company's stock price to reach $61.75 in the next year. This suggests a possible upside of 204.6% from the stock's current price.
View analysts price targets for KALA or view top-rated stocks among Wall Street analysts.

Kala Pharmaceuticals' stock was trading at $38.15 at the beginning of the year. Since then, KALA stock has decreased by 46.9% and is now trading at $20.27.
View the best growth stocks for 2023 here.

Kala Pharmaceuticals saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 236,300 shares, a drop of 52.2% from the December 31st total of 494,700 shares. Based on an average daily trading volume, of 2,300,000 shares, the short-interest ratio is presently 0.1 days. Currently, 17.6% of the company's shares are sold short.
View Kala Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our KALA earnings forecast.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) released its earnings results on Tuesday, November, 8th. The company reported $19.25 earnings per share for the quarter, beating analysts' consensus estimates of $10.75 by $8.50. The company earned $0.42 million during the quarter, compared to the consensus estimate of $62.50 million. Kala Pharmaceuticals had a negative net margin of 1,383.91% and a negative trailing twelve-month return on equity of 1,320.11%.

Shares of Kala Pharmaceuticals reverse split before market open on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

1 employees have rated Kala Pharmaceuticals Chief Executive Officer Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among the company's employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

(KALA) raised $90 million in an IPO on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KALA stock can currently be purchased for approximately $20.27.

Kala Pharmaceuticals (NASDAQ:KALA) has a market capitalization of $34.60 million and generates $11.24 million in revenue each year. The company earns $-142,600,000.00 in net income (profit) each year or ($56.25) on an earnings per share basis.

The company employs 192 workers across the globe.

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The official website for the company is www.kalarx.com. The company can be reached via phone at (781) 996-5252, via email at hannah.deresiewicz@sternir.com, or via fax at 781-642-0399.